TY - JOUR
T1 - Serum calcium and phosphorus levels in patients undergoing maintenance hemodialysis
T2 - A multicentre study in Korea
AU - Kim, Gheun Ho
AU - Choi, Bum Soon
AU - Cha, Dae Ryong
AU - Chee, Dong Hyun
AU - Hwang, Eunah
AU - Kim, Hyung Wook
AU - Chang, Jae Hyun
AU - Kim, Joong Kyung
AU - Noh, Jung Woo
AU - Joo, Kwon Wook
AU - Lee, Sang Choel
AU - Han, Sang Woong
AU - Kim, Sejoong
AU - Kim, Soo Wan
AU - Shin, Sug Kyun
AU - Park, Wondo
AU - Kim, Won
AU - Huh, Wooseong
AU - Kwon, Young Joo
AU - Kang, Young Sun
N1 - Funding Information:
GH Kim has received speaker fees from and has been a consultant for AbbVie. GH Kim, BS Choi, DR Cha, EA Hwang, HW Kim, JH Chang, JK Kim, JW Noh, KW Joo, SC Lee, SW Han, SW Kim, SK Shin, WD Park, W Kim, WS Huh, and YJ Kwon have received research funding from AbbVie. DH Chee is an employee of AbbVie, and owns AbbVie Stocks. SJ Kim and YS Kang have nothing to disclose.
Funding Information:
This study was funded by AbbVie. AbbVie led development of the study design in collaboration with academic investigators and analysed the primary data. All authors contributed to design, analysis, and interpretation of these data, and reviewed, approved, and decided to publish the manuscript. The authors thank Dr MiKyung Kim (NaeClear Inc.) and Dr Jiho Kang (AbbVie) for their efforts to prepare the manuscript and Dr Joo-Hark Yi (Hanyang University Guri Hospital) and Dr Tai Yeon Koo (Seoul National University Hospital) for collecting the data for this study.
PY - 2014/3
Y1 - 2014/3
N2 - Background In many countries, nephrologists follow clinical practice guidelines for mineral bone disorders to control secondary hyperparathyroidism (SHPT) associated with abnormal serum calcium (Ca) and phosphorus (P) levels in patients undergoing maintenance hemodialysis (MHD). The Kidney Disease Outcomes Quality Initiative (KDOQI) Guidelines have long been used in Korea, and this study was undertaken to investigate the current status of serum Ca and P control in MHD patients. Methods Data were collected from a total of 1,018 patients undergoing MHD without intercurrent illness, in 17 hemodialysis centers throughout the country. Serum levels of Ca, P, and intact parathyroid hormone (iPTH) were measured over 1 year, and the average values were retrospectively analyzed. Results Serum levels of Ca, P, and the Ca×P product were 9.1±0.7 mg/dL, 5.3±1.4 mg/dL, and 48.0±13.6 mg 2/dL2, respectively. However, the percentages of patients with Ca, P, and Ca × P product levels within the KDOQI guideline ranges were 58.7%, 51.0%, and 70.7%, respectively. Of the 1,018 patients, 270 (26.5%) had iPTH >300 pg/mL (uncontrolled SHPT), whereas 435 patients (42.7%) showed iPTH <150 pg/mL. Patients with uncontrolled SHPT had significantly higher values of serum Ca, P, and Ca×P product than those with iPTH >300 pg/mL. Conclusion Despite the current clinical practice guidelines, SHPT seems to be inadequately controlled in many MHD patients. Uncontrolled SHPT was associated with higher levels of serum Ca, P, and Ca < P product, suggestive of the importance of SHPT management.
AB - Background In many countries, nephrologists follow clinical practice guidelines for mineral bone disorders to control secondary hyperparathyroidism (SHPT) associated with abnormal serum calcium (Ca) and phosphorus (P) levels in patients undergoing maintenance hemodialysis (MHD). The Kidney Disease Outcomes Quality Initiative (KDOQI) Guidelines have long been used in Korea, and this study was undertaken to investigate the current status of serum Ca and P control in MHD patients. Methods Data were collected from a total of 1,018 patients undergoing MHD without intercurrent illness, in 17 hemodialysis centers throughout the country. Serum levels of Ca, P, and intact parathyroid hormone (iPTH) were measured over 1 year, and the average values were retrospectively analyzed. Results Serum levels of Ca, P, and the Ca×P product were 9.1±0.7 mg/dL, 5.3±1.4 mg/dL, and 48.0±13.6 mg 2/dL2, respectively. However, the percentages of patients with Ca, P, and Ca × P product levels within the KDOQI guideline ranges were 58.7%, 51.0%, and 70.7%, respectively. Of the 1,018 patients, 270 (26.5%) had iPTH >300 pg/mL (uncontrolled SHPT), whereas 435 patients (42.7%) showed iPTH <150 pg/mL. Patients with uncontrolled SHPT had significantly higher values of serum Ca, P, and Ca×P product than those with iPTH >300 pg/mL. Conclusion Despite the current clinical practice guidelines, SHPT seems to be inadequately controlled in many MHD patients. Uncontrolled SHPT was associated with higher levels of serum Ca, P, and Ca < P product, suggestive of the importance of SHPT management.
KW - Calcium
KW - Hemodialysis
KW - Intact parathyroid hormone
KW - Phosphorus
KW - Secondary hyperparathyroidism
UR - http://www.scopus.com/inward/record.url?scp=84897403111&partnerID=8YFLogxK
U2 - 10.1016/j.krcp.2013.12.003
DO - 10.1016/j.krcp.2013.12.003
M3 - Article
AN - SCOPUS:84897403111
SN - 2211-9132
VL - 33
SP - 52
EP - 57
JO - Kidney Research and Clinical Practice
JF - Kidney Research and Clinical Practice
IS - 1
ER -